The $582,473 grant will fund research to develop Biodel’s ultra-rapid-acting insulin product candidate at high concentrations suited to provide sufficient quantities of insulin in an external artificial pancreas pump device that has a limited volume capacity.
Concentrated formulations of Biodel’s ultra-rapid-acting insulin may be absorbed rapidly than existing concentrated insulin formulations and may therefore become an important component of an effective step in the development of an artificial pancreas, according to Biodel.
Biodel president and CEO Dr. Errol De Souza said, "These funds will be focused on applying our proprietary technology for the development of ultra-rapid-acting insulin formulations for the treatment of insulin resistant patients and to assist in the development of effective artificial pancreas therapy."
This research is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number R43DK096604.